VEGFC and prostate carcinoma: Furthermore, a soluble splice variant of NRP2, s9NRP2, has been shown to scavenge VEGF-C away from the functional complex and inhibit the formation of prostatospheres by a human prostate carcinoma cell line [108], suggesting that s9NRP2 could potentially be used to inhibit pathological VEGF-C/NRP2 signalling in prostate cancer [108].